Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3801 - 3808 of 12029 results
California AG Announces CCPA Regulations are Final – And Effective Immediately
August 17, 2020| Blog| Viewpoint
Is it Time to Appoint a New Director? Five Corporate Governance Considerations for Board Members
August 17, 2020| Blog| Viewpoint
Litigation Leaders: Mintz Levin’s Scott Ford on ‘Turning Good Lawyers into Great Ones’
August 17, 2020| News
How A PR Error Might Absolve Kodak Of Insider Trading Charges
August 16, 2020| News
SEC Risk Alert Addresses COVID-19 Compliance Risks and Considerations
August 14, 2020| Blog| Viewpoint
Massachusetts Department of Family and Medical Leave Finalizes Revised Regulations: Here’s What You Need to Know
August 13, 2020| Blog| Viewpoint
Massachusetts Paid Family and Medical Leave 2020 Regulations – Focus on the Private Plan Exemption
August 13, 2020| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|